Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Continued User Growth Is Going to Send SNAP Stock Higher

By Chris Lau, InvestorPlace Contributor

Today, user growth is lifting Snap stock. Developments in AR may sustain Snapchat’s growth in the coming years.

iQiyi Stock Could Be Trading Above $20 in No Time

By Chris Lau, InvestorPlace Contributor

China-based companies including Alibaba Group (NYSE:BABA) and Baidu, Inc. (NASDAQ:BIDU) staged a rebound on the stock market. Yet iQiyi (NASDAQ:IQ) gave up its rally back…

Aphria Stock Has the Best Chances of Soaring High in the Pot Market

By Chris Lau, InvestorPlace Contributor

Aphria has a strong brand, independent management and plenty of cash on the books to fund its expansion. How will Aphria stock fare next?

Why the Rally in Amarin Stock Should Hold Strong

By Chris Lau, InvestorPlace Contributor

Amarin's Vascepa drug should be approved for expanded use soon. This should boost Amarin stock, which makes AMRN a solid buy right now.

User Growth Is the Biggest Catalyst for Apple Stock

By Chris Lau, InvestorPlace Contributor

Apple stock is already up sharply this year. Looking ahead, its Services unit is building momentum. The iPhone 11 series enjoys wide appeal.

Load More